Status:
COMPLETED
An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Anemia
Eligibility:
All Genders
18+ years
Brief Summary
This observational study will evaluate the efficacy and safety of epoetin beta (NeoRecormon) in participants with symptomatic anemia and cancer receiving chemotherapy. Participants receiving NeoRecorm...
Eligibility Criteria
Inclusion
- Adults greater than or equal to (≥) 18 years of age
- Participants with solid tumors or lymphoproliferative disease
- Participants receiving chemotherapy
- Participants for whom erythropoietin is indicated for pre-study Hb level and observed anemic symptoms: Hb less than (\<) 11 g/dL or 6.83 millimoles per liter (mmol/L)
- ECOG performance status of 0, 1, or 2
Exclusion
- Resistant hypertension
- Acute chronic bleeding within 3 months prior to study
- Iron deficiency that is unmanageable prior to study
- Hypersensitivity to the active substance or any of the excipients of the product
- Pregnant or breastfeeding women
- Epoetin treatment within 6 months prior to study
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
1167 Patients enrolled
Trial Details
Trial ID
NCT01809314
Start Date
March 1 2008
End Date
October 1 2009
Last Update
August 19 2016
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Budapest, Hungary, 1031
2
Budapest, Hungary, 1076
3
Budapest, Hungary, 1082
4
Budapest, Hungary, 1083